Clinical trials of carvedilol in heart failure

Heart Failure Reviews

Volumn 4, Issue 1, 1999, Pages 79-88

  Tang, W H Wilson ^a   Fowler, Michael B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta adrenergic antagonists; Carvedilol; Clinical trials; Heart failure

Indexed keywords

CARVEDILOL; PLACEBO;

BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MORTALITY; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; VERTIGO;

EID: 0032843938     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009859902685     Document Type: Review

References (55)

1. Mann DL. Basic mechanisms of disease progression in the failing heart: The role of excessive adrenergic drive. Prog Cardiovasc Dis 1998;48:1-8.
2. Joseph J, Gilbert EM. The sympathetic nervous system in chronic heart failure. Prog Cardiovasc Dis 1998;48:9-16.
3. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
4. Zannad F. Over 20 years' experience of beta-blockade in heart failure. Prog Cardiovasc Dis 1998;41:31-37.
5. Packer M. Beta-adrenergic blockade in chronic heart failure: Principles, progress, and practice. Prog Cardiovasc Dis 1998;41:39-52.
6. Feuerstein GZ, Bril A, Ruffolo RR Jr. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997;80: 41L-45L.
7. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: A double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
8. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, et al. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995;92:1499-1506.
9. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1994;24:1678-1687.
10. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
11. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-380.
12. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J MeA 1991;325:303-310.
13. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
14. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
15. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
16. Follath F, Cleland J, Klein W, Murphy R. Etiology and response to drug Treatment in Heart Failure. J Am Coll Cardial 1998;32:1167-1172.
17. Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1963;34:320-324.
18. Epstein S, Braunwald E. The effect of beta-adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;75:20.
19. Das Gupta P, Broadhurst P, Raftery EB, Lahiri A. Value of carvedilol in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:1118-1123.
20. Fowler MB, Colucci WS, Bristow MR, Packer M, Gilbert EM, JN C, Wu B, Hu JZ, Ma L, Kubo S. Tolerability of carvedilol initiation in heart failure patients. J Am Coll Cardiol 1997;29:285A.
21. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail 1997;3:173-179.
22. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 1996;94:2800-2806.
23. MacDonald PS, Keogh AM, Aboyoun C, Lund M, Amor R, McCaffrey DJ. Tolerability and efficacy of carvedilol in patients with NYHA Class IV heart failure. J Am Coll Cardiol 1999;33:923-31.
24. Sackner-Bernstein MD, Lukas MA, Wu B. Evidence against heart rate reduction as the primary mechanism of action of carvedilol in chronic heart failure. J Am Coll Cardiol 1998 31:32A.
25. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-218.
26. van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol 1998;32:S31-S35.
27. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-1066.
28. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996;94:2807-2816.
29. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-1191.
30. Swedberg K, Califf R, Adams K, Gheorghiade M, Harrel F, McKenna W, Schulman K, Soler-Soler J, Uretsky B, Zannad F, for the FIRST Investigators. Six minute walk test gives prognostic information in severe heart failure. J Am Coll Cardiol 1995;25:339A.
31. Roul G, Germain P, Bareiss P. Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure? Am Heart J 1998;136:449-457.
32. Metra M, Nodari S, Raccagni D, Garbellini M, Boldi E, Bontempi L, Gaiti M, Dei Cas L. Maximal and submaximal exercise testing in heart failure. J Cardiovasc Pharmacol 1998; 32:S36-S45.
33. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-2799.
34. Feuerstein G, Yue TL, Ma X, Ruffolo RR. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;48:17-24.
35. Ruffolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998;32: S22-S30.
36. Krum H, Gu A, Wilshire-Clement M, Sackner-Bernstein J, Goldsmith R, Medina N, Yushak M, Miller M, Packer M. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am Heart J 1996;131:337-341.
37. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996;27:532-538.
38. Kukin ML, Kaiman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, Eng C. Antioxidant effects of carvedilol and metoprolol in congestive heart failure. J Am Coll Cardiol 1998;29:189A.
39. McMurray J, Chopra M, Abdullah I, Smith E, Dargie J. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 1993;14:1493-1498.
40. Colucci WS, Packer M, Bristow MB, Fowler MB, Gilbert EM, Cohn JN, Young ST, Shusterman NH. Carvedilol reduces clinical progression in patients with moderate-severe heart failure. J Am Coll Cardiol 1997;29:63A.
41. Gilbert EM, Shusterman N, Young S. Carvedilol reduces the risk of clinical deterioration in chronic heart failure. Circulation 1996;94:I-664.
42. Gilbert EM, Lukas MA, Wu B, Fowler MB. Effects of carvedilol on symptom score in heart failure. J Am Coll Cardiol 1998;31:32A.
43. Oster G, Menzin J, Richner RE, Young S, Vera M, Fowler MB. Impact of Carvedilol therapy for heart failure on costs of cardiovascular-related hospitalization. J Am Coll Cardiol 1997;29:326A.
44. Bristow MB, Em G, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Robertson AD, Krueger S. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Circulation 1996;94:I-664.
45. Bristow MR, Gilbert EM, Packer M, Colucci WS, Lukas MA, Fowler MB, Cohn JN. Effects of carvedilol in elderly patients with chronic heart failure. Circulation 1997;96:I-577.
46. Yancy C, Fowler MB, Colucci WS, Gilbert EM, Lukas MA, Young ST. Response of black heart failure patients to carvedilol. J Am Coll Cardiol 1997;29:284A.
47. Gilbert EM, Colucci WS, Fowler MB, Lukas MA, Young ST, Hirshberger R, Adams K, de Marchens E, Kreuger S, Karlsburg R, Liang CS. Carvedilol without ACE inhibition in the treatment of patients with moderate to severe chronic heart failure. Circulation 1996;94:I-663.
48. Bristow MR, Colucci WS, Fowler MB, Gilbert EM, Lukas MA, Young ST, Hirshberger R, Adams K, Kreuger S, Melman H, Liang CS. Effect of carvedilol on survival and hospitalization in patients with ischemic or non-ischemic cardiomyopathy. Circulation 1996;94:I-338.
49. Packer M, Colaii WS, Cohn JN, et al. Relationship between long-term changes in left ventricular function and clinical outcomes in patients with chronic heart failure treated with carvedilol. J Am Coll Cardiol 1997;29:64A.
50. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomized trial. Lancet 1999;353:9-13.
51. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta-blocker therapy on mortality in patients with heart failure. A systematic overview of randomized controlled trials. Eur Heart J 1997;18:560-565.
52. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
53. Schmidt BM, Janson CP, Wehling M. Assuming the worst may not be had at all. Carvedilol in heart failure treatment. Eur J Clin Pharmacol 1998;54:281-285.
54. Press Realese by Astra Pharmaceuticals. Use of The Beta Blocker Metroprolol Cr/X1 In Heart Failure Patients Significantly Improves Survival.1998.
55. O'Connor CM, Gattis WA, Swedberg K. Current and novel pharmacologic approaches in advanced heart failure. Am Heart J 1998;135:S249-S263.